The Ulutas Medical Journal p-ISSN 2149-0430 e-ISSN 2149-388X

The Ulutas Medical Journal · ISSN 2149-0430 (印刷版), 2149-388X (在线版) · https://www.ulutasmedicaljournal.com/?mno=268872

短篇通讯 · 开放获取

血浆酸在心血管疾病中的争议作用

标题、摘要和全文为机器翻译。 英文原文

  • Alexander E Berezin1
  1. Private Clinic "Vita-Center", 3, Sedova str., Zaporozhye, Ukraine Senior Consultant of Therapeutic Unit, Internal Medicine Department, State Medical University of Zaporozhye, 26, Mayakovsky av., Zaporozhye, Ukraine ROR
下载 PDF (222.2 KB) 引用方式 doi:10.5455/umj.20170608022350

摘要

之前的临床,观察和流行病学研究表明,血清尿酸(SUA)与心血管疾病(血肿,心力衰竭,无症状性心肌硬化),代谢状态(腹部肥胖,糖尿病,代谢综合征,胰岛素抗药性)和肾脏疾病之间有很强的联系. 有大量证据表明,SUA在普通人群和已确诊的CV疾病和代谢疾病的个人中作为CV事件和CV死亡率的预测者的作用。 然而,SUA可能会对内分泌和挥发产生保护作用,并通过对细胞前体的挤压和分化,对内分泌修复系统产生减弱作用。 虽然SUA降低药物被广泛用于症状性高血压和痛楚超过其病原体的患者,但对于肾损伤和CV疾病的无症状者,SUA低于目标水平6.0毫克/日升,并没有得到同意,有关这些患者的数据也非常有限。 短篇的交流描写了SUA作为初级细胞毒性剂和次级细胞保护者对缺氧,异血症和opoptosis的争议作用.

关键词

全文

全文为机器翻译；以英文原文为准。 英文原文

导言

血清尿酸(SUA)被认为是普通人群心血管(CV)事件和CV疾病的一个独立风险因素 (1, 2)虽然SUA水平高于目前的国际参考限值,相当于6毫克/升,在慢性肾病中非常普遍,但是由于心肌梗塞、中风、高血压、心力衰竭、心律失常、休克败血症等多种原因,在住院者中与医院内CV死亡率密切相关。 (3–6)有大量证据表明,SUA可能是肾损伤、氧化性应激、无症状性心肌硬化、胰岛素抗药性及炎症的有价值的和强大的生物标志。 (5–9)因此,最近的临床研究显示,通过静脉血压中反应性氧物种的积累,SUA与动脉高血压前内皮功能障碍的发育相吻合。 (10, 11)虽然SUA降低药物(allopurinol, febuxostat)被广泛用于症状性高血压和痛楚超过其病原体的患者,但对于肾损伤和CV疾病的无症状者,SUA在目标水平6mg/dL以下,并没有得到同意,有关这些患者的数据也非常有限。

然而,SUA在CV开发中的作用似乎存在严重争议. (12)作为自由基的拾荒者,SUA有助于调节氧化性应力,并可能对缺氧症、异血症和鼠疫表现出强大的保护作用。 因此,SUA减轻目标器官(即心脏、肺和肾脏)普遍微血管功能障碍,并抑制表层局部炎症。 (3, 13)通过配合内皮先天细胞和其他细胞前体的移动和分化,SUA可能是血管修补系统的内源调节器 (14). 有证据表明,尿酸可调节分泌物,通过细胞内先天信号系统(Akt,STAT3),它可调解释放分泌物进行循环,包括微粒子和微囊。 (15, 16)最后,SUA在内部修理系统方面发挥关键作用,有助于增强内分泌和挥发性 (17)因此,SUA可能会通过自由基积累的衰减而直接伤害细胞膜,与此形成对比的是,它通过涉及先天细胞和改善细胞间合作,显示出对低氧、异血症后组织恢复的间接影响。

可能,SUA在低级炎症、组织损伤和内生修复系统之间起到促进作用。 (18)事实上,Xanthine oxidase(XO)的活性增加,它是尿酸合成中的一个关键酶,并且正在控制着炎症细胞基因子/化学因子,一些生长因子和中间体(血葡萄糖),在一些患者体内发现了新陈代谢综合征、糖尿病、腹部肥胖、心力衰竭、肝硬化、风湿病。 因此,XO在表达上可能不仅是防止活性氧种积累的保护性假定机制,也可能是特定分泌物修饰剂,成为细胞前体流动和分化的重要核心工具之一。 (19)在这方面,将无症状的SUA水平降低到6毫克/dL以下,而不论所称的CV事件和CV疾病的风险如何,都需要详细解释。 (12)。 。 。

结论

综上所述,需要进入大型临床试验来调查SUA在CV疾病的病因和结果中具有争议性的作用,特别是在SUA在临床上没有显著提升,可能不需要对低血清浓度做出决策的情况下.

声明

作者贡献（CRediT）
所有作者对全部 14 项 CRediT 角色贡献均等（Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing）。
资助

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

利益冲突
A conflict of interest statement was not reported in the published version of this article.
伦理批准
Ethics approval details were not reported in the published version of this article.
数据可用性
A data availability statement was not reported in the published version of this article.

参考文献 (19)

19 条参考文献中有 16 条已链接 DOI。

  1. Scheepers LEJM, Boonen A, Dagnelie PC, Schram MT, van der Kallen CJH, Henry RMA, et al. Uric acid and blood pressure: exploring the role of uric acid production in the Maastricht study. J Hypertens. 2017.. DOI Crossref PubMed Google Scholar
  2. Lai CL, Xing JP, Liu XH, Qi J, Zhao JQ, Ji YR, et al. Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hyperten sion Patients. Chin Med J (Engl). 2017;130(11):1296-1302. DOI Crossref PubMed Google Scholar
  3. Magnoni M, Berteotti M, Ceriotti F, Mallia V, Vergani V, Peretto G, et al. Serum uric acid on admission predicts in-hospital mortality in patients with acute coronary syndrome. Int J Cardiol. 2017. pii: S0167-5273(17)30712- X. DOI Crossref PubMed Google Scholar
  4. Berezin AE. Prognostication in different heart failure phenotypes: the role of circulating biomarkers. Journal of Circulating Biomarkers. 2016, 5:01. DOI Crossref PubMed Google Scholar
  5. Berezin AE, Kremzer AA. Serum uric acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiology Research and Practice. 2013, Article ID 129369,7p. DOI Crossref PubMed Google Scholar
  6. Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA, Zulli A, et al. The utility of biomarker risk Serum Uric Acid in Cardiovascular Diseases Alexander E. Berezin, et al. prediction score in patients with chronic heart failure. Int J ClinExp Med 2015;8(10):18255 -64. DOI Crossref PubMed Google Scholar
  7. Lai S, Mariotti A, Coppola B, Lai C, Aceto P, DimkoMet al. Uricemia and homocysteinemia: nontraditional risk factors in the early stages of chronic kidney disease--preliminary data. Eur Rev Med Pharmacol Sci. 2014;18(7):1010-7. PubMed Google Scholar
  8. Krajcoviechova A, Tremblay J, Wohlfahrt P, Bruthans J, Tahir MR, Hamet P, et al. The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome. Am J Hypertens. 2016;29(12):1335-1342. DOI Crossref PubMed Google Scholar
  9. Geraci G, Mulè G, Morreale M, Cusumano C, Castiglia A, et al. Association between uric acid and renal function in hypertensive patients: which role for systemic vascular involvement?J Am SocHypertens. 2016;10(7):559-569. DOI Crossref PubMed Google Scholar
  10. Bharti S, Bharti B. Serum Uric Acid and Childhood Hypertension: Association to Causation to Prevention. Am J Hypertens. 2017. DOI Crossref PubMed Google Scholar
  11. Berezin AE. Biological markers of cardiovascular diseases. Part 4. Diagnostic and prognostic value of biological markers at risk stratification among patients with heart failure. LAMBERT Academic Publishing GmbH, Moskow, 2015-329 p. PubMed Google Scholar
  12. Hsieh CH, Lin JD, Wu CZ, Hsu CH, Pei D, Liang YJ, et al. Is lower uric acid level better? A combined cross-sectional and longitudinal study in the elderly. Endocrine. 2014;47 (3):806-15. DOI Crossref PubMed Google Scholar
  13. Wijnands JM, Houben AJ, Muris DM, Boonen A, Schram MT, Sep SJ, et al.Uric acid and skin microvascular function: the Maastricht study.J Hypertens. 2015; 33(8):1651-7. DOI Crossref PubMed Google Scholar
  14. Berezin AE, Kremzer AA. Analysis of Various Subsets of Circulating Mononuclear Cells in Asymptomatic Coronary Artery Disease. J. Clin. Med. 2013; 2: 32-44. DOI Crossref PubMed Google Scholar
  15. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neuro oncol. 2013; 113, 1–11. DOI Crossref PubMed Google Scholar
  16. Berezin AE. Microparticles in Chronic Heart Failure. Advances in Clinical Chemistry / 1st Edition. Serial Editors: Gregory S. Makowski 2017; Vol. 79, 1-252 p. DOI Crossref PubMed Google Scholar
  17. Berezin AE, Kremzer AA, Berezina TA, MartovitskayaYuV. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis. ActaClinicaBelgica: International Journal of Clinical and Laboratory Medicine. 2016; 71 (1):38-45. DOI Crossref PubMed Google Scholar
  18. Berezin AE. Biomarkers for cardiovascular risk in diabetic patients. Heart. 2016;102:1939-1941. PubMed Google Scholar
  19. Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA. Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients. J CardiovascThorac Res, 2014;6(3):153-62. DOI Crossref PubMed Google Scholar

阅读全文

在此打开 PDF

正在加载 PDF…

若 PDF 未在此显示，请使用上方的下载按钮。

如何引用本文

Berezin AE. The Controversial Role of Serum Uric Acid in Cardiovascular Diseases. Ulutas Med J. 2017;3(3):54-56. doi:10.5455/umj.20170608022350

Berezin, A. E. (2017). The Controversial Role of Serum Uric Acid in Cardiovascular Diseases. The Ulutas Medical Journal, 3(3), 54–56. https://doi.org/10.5455/umj.20170608022350

Berezin, A.E. (2017) 'The Controversial Role of Serum Uric Acid in Cardiovascular Diseases', The Ulutas Medical Journal, 3(3), pp. 54–56. doi: 10.5455/umj.20170608022350.

RIS (EndNote, Zotero) BibTeX JATS XML
在您的网站中嵌入本文

将此代码粘贴到您的页面。卡片显示标题、作者和 DOI，并链接回本文。

报告不一致
投稿 联系我们